Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1968 1
1971 1
1983 1
1986 1
1993 1
1998 1
2002 1
2003 1
2005 1
2008 1
2009 1
2010 1
2011 2
2013 1
2014 2
2015 1
2016 3
2017 5
2018 7
2019 16
2020 29
2021 31
2022 36
2023 37
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Lederwasch
Page 1
Cholesterol and matrisome pathways dysregulated in astrocytes and microglia.
Tcw J, Qian L, Pipalia NH, Chao MJ, Liang SA, Shi Y, Jain BR, Bertelsen SE, Kapoor M, Marcora E, Sikora E, Andrews EJ, Martini AC, Karch CM, Head E, Holtzman DM, Zhang B, Wang M, Maxfield FR, Poon WW, Goate AM. Tcw J, et al. Cell. 2022 Jun 23;185(13):2213-2233.e25. doi: 10.1016/j.cell.2022.05.017. Cell. 2022. PMID: 35750033 Free PMC article.
CRISPRi screens in human iPSC-derived astrocytes elucidate regulators of distinct inflammatory reactive states.
Leng K, Rose IVL, Kim H, Xia W, Romero-Fernandez W, Rooney B, Koontz M, Li E, Ao Y, Wang S, Krawczyk M, Tcw J, Goate A, Zhang Y, Ullian EM, Sofroniew MV, Fancy SPJ, Schrag MS, Lippmann ES, Kampmann M. Leng K, et al. Nat Neurosci. 2022 Nov;25(11):1528-1542. doi: 10.1038/s41593-022-01180-9. Epub 2022 Oct 27. Nat Neurosci. 2022. PMID: 36303069 Free PMC article.
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Lin NU, et al. JAMA Oncol. 2023 Feb 1;9(2):197-205. doi: 10.1001/jamaoncol.2022.5610. JAMA Oncol. 2023. PMID: 36454580 Free PMC article. Clinical Trial.
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.
Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanović B, Murphy K, Wang B, Qiu X, Endress JE, Reyes J, Lim K, Font-Tello A, Syamala S, Xiao T, Reddy Chilamakuri CS, Papachristou EK, D'Santos C, Anand J, Hinohara K, Li W, McDonald TO, Luoma A, Modiste RJ, Nguyen QD, Michel B, Cejas P, Kadoch C, Jaffe JD, Wucherpfennig KW, Qi J, Liu XS, Long H, Brown M, Carroll JS, Brugge JS, Bradner J, Michor F, Polyak K. Shu S, et al. Mol Cell. 2020 Jun 18;78(6):1096-1113.e8. doi: 10.1016/j.molcel.2020.04.027. Epub 2020 May 15. Mol Cell. 2020. PMID: 32416067 Free PMC article.
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.
Wang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK, Hughes ME, He X, Xie S, Jiang T, Wang W, Zoeller JJ, Kim HJ, Roberts TM, Konstantinopoulos PA, Matulonis UA, Dillon DA, Winer EP, Lin NU, Zhao JJ. Wang Q, et al. Nat Commun. 2022 May 31;13(1):3022. doi: 10.1038/s41467-022-30568-1. Nat Commun. 2022. PMID: 35641483 Free PMC article.
The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.
Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, Lavin Y, Rizvi H, Tischfield SE, Quintanal-Villalonga A, Chan JM, Shah N, Allaj V, Manoj P, Mattar M, Meneses M, Landau R, Ward M, Kulick A, Kwong C, Wierzbicki M, Yavner J, Egger J, Chavan SS, Farillas A, Holland A, Sridhar H, Ciampricotti M, Hirschhorn D, Guan X, Richards AL, Heller G, Mansilla-Soto J, Sadelain M, Klebanoff CA, Hellmann MD, Sen T, de Stanchina E, Wolchok JD, Merghoub T, Rudin CM. Chow A, et al. Immunity. 2023 Jan 10;56(1):93-106.e6. doi: 10.1016/j.immuni.2022.12.001. Epub 2022 Dec 26. Immunity. 2023. PMID: 36574773 Free PMC article.
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C, Keany MP, Dong H, Al-Alem LF, Pandya UM, Lazo S, Boehnke K, Lynch KN, Xu R, Zarrella DT, Gu S, Cejas P, Lim K, Long HW, Elias KM, Horowitz NS, Feltmate CM, Muto MG, Worley MJ Jr, Berkowitz RS, Matulonis UA, Nucci MR, Crum CP, Rueda BR, Brown M, Liu XS, Hill SJ. Wan C, et al. Cancer Res. 2021 Jan 1;81(1):158-173. doi: 10.1158/0008-5472.CAN-20-1674. Epub 2020 Nov 6. Cancer Res. 2021. PMID: 33158814 Free PMC article.
174 results